Respiratory failure & ventilation
Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning
Authors' conclusion
Based on these exploratory findings, improved weaning rates with tDNS will likely lead to meaningful cost savings in acute and long-term care settings, and concurrent long-term QALY gains that, depending on therapy cost, may render tDNS a cost-effective, high-value intervention.
Study context
- Population
- Mechanically ventilated patients, US setting (RESCUE-3 randomised trial data and real-world claims data)
- Comparison
- Transvenous diaphragm neurostimulation (tDNS) vs standard of care (SoC) for ventilator weaning
- Outcome
- Stakeholder-specific incremental costs and QALY gain with tDNS
Methodological detailsexploratory, lifetime projection model, sensitivity analyses
- Exploratory
- Lifetime projection model
- Sensitivity analyses
Main finding
As reported in the abstract
Projected cost savings with tDNS, acute setting (before tDNS cost)
$12,102
Projected cost savings with tDNS, long-term care hospital setting (before tDNS cost)
$11,999
Quality-adjusted life-year (QALYs) gained with tDNS over remaining lifetime
0.10-0.68
Further findings
Sensitivity analyses
- Favorable cost savings across a range of clinical and cost assumptions
Original publication
Health-Economic Value of Transvenous Diaphragm Neurostimulation in Ventilator Weaning. Crit Care Med. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →